Is STJ a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,550 people get STJ articles and Market Currents by email alert.

Get email alerts on STJ »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

St. Jude Medical Boosts Anti-Pain Portfolio In $40M Deal
Alan Kotok • Sun, Jun 9
Investors Should Assign A Fair Value Range To St. Jude
Valuentum • Thu, Jun 6
Lead Situation Improves For St. Jude, But The Future Could Be Wireless
EP Vantage • Fri, May 10
Billions In Renal Denervation: Medtronic, St. Jude
Peter Geschek • Fri, May 10 • 1 Comment
St. Jude Medical Outperforming Peers In The Wake Of Key Cardiac Development
Heather Ingrassia • Sun, Mar 10 • 4 Comments
St. Jude's Rally Has Taken Away The Easy Money
Stephen Simpson • Wed, Jan 23
Buy St. Jude Medical On The Dip
Canadian Dividend Growth Investor • Tue, Dec 4, 2012 • 10 Comments
Boston Scientific Could Benefit From St. Jude Medical's Troubles
Trefis • Tue, Nov 27, 2012
St. Jude's Amplatzer Can't Cure A Broken Heart
EP Vantage • Fri, Oct 26, 2012 • 1 Comment
Stagnant Performance, FDA Issues Thump St. Jude
Stephen Simpson • Thu, Oct 18, 2012 • 12 Comments
Why St. Jude Is Poised To Become A Solid Income Stock
Valuentum • Thu, Sep 20, 2012
St. Jude Medical's Weaker Guidance Presents Another Opportunity
Stephen Simpson • Wed, Jul 18, 2012
Why We Think St. Jude Is Undervalued
Valuentum • Thu, May 17, 2012 • 4 Comments
An Exciting New Technology That Could Take Pressure Off St. Jude Medical
Alan Brochstein • Wed, May 16, 2012 • 14 Comments
St. Jude Offers Undervalued Growth And Overstated Risk
Stephen Simpson • Thu, Apr 19, 2012 • 2 Comments
St. Jude Medical: Earnings Preview
Zacks Investment Research • Sat, Apr 14, 2012 • 1 Comment
For St. Jude Bulls, It's A Question Of Faith
Stephen Simpson • Thu, Jan 26, 2012 • 10 Comments
St. Jude Medical: Earnings Preview
Zacks Investment Research • Wed, Jan 25, 2012
Quality, With A Dividend, Now On Sale: St. Jude Medical
K202 • Tue, Jan 10, 2012
St. Jude Remains On Our Dividend Growth Watch List
Valuentum • Wed, Jan 4, 2012

To learn more about Seeking Alpha Pro, click here.

Top 10 Net Payout Yield Stocks For June 2013
Stone Fox Capital • Mon, Jun 10
How To Play The Invest-For-Tomorrow Game In Medtech: Alan Brochstein
Life Sciences Report • Thu, Jun 6 • 1 Comment
Johnson & Johnson: Part V - Unacceptable Earnings Growth Decline - Reversal Strategy
Robert Honeywill • Thu, Jun 6
Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates
Robert Honeywill • Thu, May 23 • 12 Comments
Johnson & Johnson: At The Crossroads - Part II
Robert Honeywill • Fri, May 10 • 1 Comment
Alphabet Soup
George Acs • Sun, May 5 • 2 Comments
Stryker: Positioned To Stay Ahead Of The Game, But Will Company Keep Pace?
Emerging Equities • Tue, Apr 23
5 Cheap Dividend Stocks Worth Investigating
Marshall Hargrave • Tue, Mar 26
Heartware's Public Offering: Takeover Bid For Sunshine Heart?
Robert Honeywill • Thu, Mar 21 • 3 Comments
Challenging Future For The Medical Devices Industry
Richard Richter • Tue, Mar 12 • 3 Comments
HeartWare Is Premium-Priced Growth, But Could Still Go Higher
Stephen Simpson • Thu, Mar 7 • 8 Comments
Ray Dalio Is Bullish On These 5 Dividend Stocks
Dividendinvestr • Tue, Mar 5 • 1 Comment
AtriCure's Frustratingly Slow Build Hides Value Beneath
Stephen Simpson • Mon, Mar 4
Fortune Could Favor A Bolder Terumo
Stephen Simpson • Thu, Feb 21
Risky Sunshine Heart Looks Very Interesting
Stephen Simpson • Thu, Feb 21 • 15 Comments
Growth Needs Resuscitation, But Medtronic Still Looks Like A Value
Stephen Simpson • Wed, Feb 20 • 3 Comments
Thoratec And Heartware Vying For Leadership In Implantable Heart Failure Devices
Stock Traders Daily • Wed, Feb 13 • 6 Comments
TAVR Is Real (And Maybe Spectacular), But Edwards Lifesciences Isn't A Bargain
Stephen Simpson • Thu, Feb 7
5 Dividend Picks From The Eagle Growth & Income Fund
Dividendinvestr • Mon, Feb 4 • 1 Comment
Is It Finally The Right Time For Boston Scientific?
Stephen Simpson • Wed, Jan 30

St. Jude Medical's Management Presents at 38th Annual Deutsche Bank Health Care Conference (Transcript)
Wed, May 29
St. Jude Medical Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 17
St. Jude Medical's Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
St. Jude Medical Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Jan 23
St. Jude Medical Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 17, 2012 • 1 Comment
St. Jude Medical Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Jul 18, 2012
St. Jude Medical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Wed, Apr 18, 2012
St. Jude Medical Inc. - Analyst/Investor Day
Fri, Feb 3, 2012
St. Jude Medical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Jan 25, 2012
St. Jude Medical's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Wed, Oct 19, 2011 • 3 Comments
St. Jude Medical's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Wed, Jul 20, 2011
St. Jude Medical's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Wed, Apr 20, 2011
St. Jude Medical's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Wed, Jan 26, 2011
St. Jude Medical CEO Discusses Q3 2010 Results - Earnings Call Transcript
Wed, Oct 20, 2010
St. Jude Medical Q2 2010 Earnings Call Transcript
Thu, Jul 22, 2010
St. Jude Medical Inc. Q1 2010 Earnings Call Transcript
Wed, Apr 21, 2010
St. Jude Medical Inc. Q4 2009 Earnings Call Transcript
Wed, Jan 27, 2010
St. Jude Medical Inc., Q3 2009 Earnings Call Transcript
Wed, Oct 21, 2009
St. Jude Medical, Inc. Q2 2009 Earnings Call Transcript
Wed, Jul 22, 2009
St. Jude Medical, Inc. Q1 2009 Earnings Call Transcript
Wed, Apr 22, 2009 • 1 Comment

St. Jude Medical Announces FDA Approval of High-Voltage Devices with New Safety Features

Business Wire (Jun 11, 2013)
St. Jude Medical Signs Equity Investment and Option to Purchase Agreement with Spinal Modulation

Business Wire (Jun 7, 2013)
St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

Business Wire (Jun 4, 2013)
London Markets: U.K. stocks slide as miners drop on China data

at MarketWatch.com (May 23, 2013)
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology

Business Wire (May 23, 2013)
St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session

Business Wire (May 21, 2013)
St. Jude Medical to Present at the 38th Annual Deutsche Bank Health Care Conference

Business Wire (May 21, 2013)
St. Jude Medical Announces European Approval of 3-D Vessel Reconstruction Technology to Aid Physicians in Stent Placement

Business Wire (May 16, 2013)
St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System

Business Wire (May 14, 2013)
St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013

Business Wire (May 9, 2013)
St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices

Business Wire (May 8, 2013)
St. Jude Medical to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire (May 3, 2013)
St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study

Business Wire (May 2, 2013)
St. Jude Medical Announces Second Quarter Dividend

Business Wire (May 1, 2013)
St. Jude Medical Announces CE Mark and Launch of First Quadripolar CRT Pacemaker

Business Wire (Apr 30, 2013)
St. Jude Medical Reports First Quarter 2013 Results

Business Wire (Apr 17, 2013)
Fight or Flight: Get Ready for the Earnings Crush

at CNBC.com (Apr 14, 2013)
St. Jude Medical First to Receive CE Mark Approval of Deep Brain Stimulation Systems for Both Primary and Secondary Dystonia

Business Wire (Apr 10, 2013)
Early Movers: AA, JCP, MNST & More

at CNBC.com (Apr 9, 2013)
St. Jude Medical Announces First Quarter 2013 Earnings Conference Call

Business Wire (Apr 4, 2013)

STJ vs. ETF Alternatives

Company Description

St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. Our four operating... More

Sector: Healthcare

Industry: Medical Appliances & Equipment

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 12, 1:07 PM Deutsche Bank (Buy) thinks the approval of St. Jude Medical's (STJ +2.6%) implantable cardioverter and cardiac resynchronization defibrillators is a "good sign," as it may signal that STJ is "making progress" with its efforts to allay concerns tied to an FDA inspection of the company's Sylmar, California manufacturing facility. Wedbush's Tao Levy concurs, noting that the FDA "viewed the safety enhancements of the Ellipse and Assura as important enough to approve despite the warning letter." Comment! [On the Move, Healthcare]
Tuesday, June 11, 4:47 PM St. Jude Medical (STJ) says it's received FDA approval for its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. Comment! [Healthcare]
Friday, May 31, 10:53 AM Wedbush initiates several medical equipment and supply names. Rundown: Boston Scientific (BSX +0.8%), which is "progressing with its turnaround story," is started at Neutral (price target $10) with new product intros serving as "catalysts for higher EPS"; Medtronic (MDT) is started at Neutral (price target $52) and is "an 800-lb. gorilla [facing] growing competition, limited near-term growth, and an overextended valuation"; St. Jude Medical (STJ -0.9%) is started at Outperform (price target $57) as the Durata overhang "is beginning to lose some steam enabling investors to refocus on STJ's healthy pipeline." 1 Comment [Healthcare]
Tuesday, May 28, 8:43 AM Canaccord downgrades St. Jude Medical (STJ) to Sell citing "questionable earnings quality," a less-than-enthusiastic take on the company's product pipeline, the potential for CRM market share loss, and an "overextended valuation." Price target maintained at $35. 1 Comment [Healthcare]
Thursday, May 2, 2:56 PM St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 31. Ex-div date June 26. (PR) Comment! [Dividends]
Wednesday, April 17, 5:50 PM Volcano (VOLC) files a lawsuit against St. Jude Medical (STJ) for patent infringement, accusing STJ of violating its patent on certain guide wire methods used in its devices. The suit is just another salvo in an ongoing patent war between the two companies over pressure wire technology used their heart devices. The war actually began nearly three years ago, when STJ filed suit against VOLC for infringement of 5 of its own patents for pressure guide wire products. Comment! [Healthcare]
Wednesday, April 17, 8:20 AM From St. Jude's (STJ) earnings call. Lowers 2013 sales guidance to $5.36-5.48B, representing a cut of $107M at the midpoint. Analysts expect $5.7B. The lower forecast is due to changes in currency assumptions and a more cautious outlook in its cardiovascular business. Expects currency neutral sales growth of -1% to +2%. (Q1 earnings) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 17, 8:10 AM More on St. Jude Medical (STJ) Q1: net profit +5% to $223M, with the company enjoying a $21M tax benefit but taking $61M in charges, primarily related to restructuring and acquisition activities. Forex fluctuations hurt sales by $17M. Sales breakdown: Cardiac Rhythm Management -8% to $678M; Atrial Fibrillation +5% to $233M; total cardiovascular sales -2% to $328M. Expects Q2 EPS of $0.93-$0.95 vs consensus of 0.94 and FY EPS of $3.68-$3.73 vs $3.95. (PR) Comment! [Earnings]
Wednesday, April 17, 7:31 AM St. Jude Medical (STJ): Q1 EPS of $0.92 beats by $0.01. Revenue of $1.34B (-4% Y/Y) misses by $0.02B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 17, 12:05 AM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
Tuesday, April 16, 5:30 PM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
Friday, April 5, 5:00 AM St. Jude Medical (STJ) has been hit with lawsuits in California that allege that defects with the manufacturing and oversight of its now recalled Riata heart defibrillator "leads" injured or killed over 30 patients. The suits could have a wider impact, as they seek to get round a 2008 Supreme Court ruling that protected medical-device companies from product-liability claims as long as they complied with FDA standards. Comment! [Healthcare]
Friday, March 8, 2:55 PM St. Jude Medical (STJ +1.1%) is up today after the company reports the first patient implant in a new trial evaluating the company's Aplatzer Cardiac Plug, a device for the prevention of stroke. The trial is designed to determine if the device is safe and effective in preventing thrombus from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke. Comment! [Healthcare, On the Move]
Monday, February 25, 8:57 AM St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, 9% increase from prior dividend of $0.23. Forward yield 2.43%. For shareholders of record Mar. 29. Payable Apr. 30. Ex-div date Mar. 27. (PR) Comment! [Dividends]
Friday, February 15, 2:10 PM St. Jude Medical (STJ -3.4%) has been working overtime to convince the Street that its Durata heart device leads are safe, but Cowen doesn't take the bait, downgrading the stock to Market Underperform over concerns that the new heart wire is no different from the ones already taken off the market. The firm cites a "significant risk" of a recall, which would " meaningfully damage" its defibrillator and pacemaker business. Comment! [Healthcare, On the Move]
Wednesday, February 13, 9:42 AM St. Jude Medical (STJ +0.5%) has issued a voluntary Class 1 recall of its Amplatzer TorqVue FX Delivery System, which is used for hole in the heart surgery, after the company discovered that the device could fracture in a number of cases, causing serious damage and even death. However, no serious injuries have occurred.
Comment! [Healthcare]

Alan Brochstein
$STJ has had a nice run, but it's still a bit cheap to the peers despite better growth potential
May 19, 4:41 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE
May 12, 9:27 AM
Reply (1)

• !Report Abuse
View all 1 replies
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
May 12, 5:32 PM
• !Report Abuse
Add a reply...

140 characters

ltfinger
Returning Upgrades (5/6/13): $ABFS, $BLMN, $COR, $FNGN, $GEOS, $HFC, $MBI, $STJ, $VNR, $WCC, $WLK
May 7, 2:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alan Brochstein
$EW pounded on miss and lower guidance - not bad at 70, could be a buy at 68 (but I prefer $STJ)
Apr 24, 9:13 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alan Brochstein
$STJ sales reduction mainly due to stronger dollar but distributed products in Japan are under pressure too
Apr 17, 4:20 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (4/11/13): $STAG, $STAN, $STJ, $SUI, $SWM, $THG, $TXRH, $UL, $UN, $VCLK, $VOD, $WPPGY
Apr 12, 10:33 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Potential Upgrades (4/4/13): $ANF, $LULU, $PLCE, $ROK, $SHOO, $SIAL, $SNI, $SQQQ, $STJ, $TAHO
Apr 5, 12:31 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Downgrades (3/26/13): $ANN, $BECN, $CLMT, $CNC, $CYT, $FIVE, $ITW, $MOS, $MSM, $PANL, $QCOR, $SAP, $SFLY, $STJ, $THO, $VAR, $VIAB, $WCG
Mar 27, 3:41 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alan Brochstein
Nice action on $STJ
Jan 26, 3:16 PM
Reply (5)

• !Report Abuse
View all 5 replies
weed: Increased coverage is why I've had my eye on $DVA and $RMD, but I think I missed the boat. These companies are dancing with the devil.
Jan 26, 4:30 PM
• !Report Abuse
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
Jan 26, 4:34 PM
• !Report Abuse
Add a reply...

140 characters

Alan Brochstein
$STJ had a nice outlook - conservative yet delivering EPS above expectations. Raising my target to 60
Jan 24, 9:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE
May 12, 9:27 AM
Reply (1)

• !Report Abuse
View all 1 replies
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
May 12, 5:32 PM
• !Report Abuse
Add a reply...

140 characters

Alan Brochstein
Nice action on $STJ
Jan 26, 3:16 PM
Reply (5)

• !Report Abuse
View all 5 replies
weed: Increased coverage is why I've had my eye on $DVA and $RMD, but I think I missed the boat. These companies are dancing with the devil.
Jan 26, 4:30 PM
• !Report Abuse
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
Jan 26, 4:34 PM
• !Report Abuse
Add a reply...

140 characters

Alan Brochstein
$STJ can't get out of its own way - 39 buyer
10/17/12
Reply (1)

• !Report Abuse
View all 1 replies
Julius Ferraro: Looking for 38-39 also
10/18/12
• !Report Abuse
Add a reply...

140 characters

sstonerm3
uh oh, red mist, starting to love my gains. Help me be rational. COV up 15% 1 month. STJ up 18% 5 weeks. Take it and Run?
1/19/12
Reply (8)

• !Report Abuse
View all 8 replies
sstonerm3: Ok I sold some. Now have baby positions, 50 shrs COV, 100 shares STJ
1/19/12
• !Report Abuse
Jeremy Johnson: STJ is not expensive, but it is getting close to fair value. Fair value stocks are still good to own... fair equity return is 8% a year.
1/25/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

Alan Brochstein
$STJ hitting guidance for Q4 is huge
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: I took profits today on the puts I had sold. Today's big move capped a nice comeback by STJ.
1/10/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Bought back some puts I sold for gains: +30% on STJ, +48% on EOG, and +88% on COP.
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: I also sold my FLR shares for no gain.
1/9/12
• !Report Abuse
Add a reply...

140 characters

moneyhawk1
GO DENVER WMT STJ DBD SJM ED
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
jason2788: go denver is right, i skipped around my house like a little school girl.
1/9/12
• !Report Abuse
Add a reply...

140 characters

Alan Brochstein
Lots of pain in med devices - STJ and ZMH stand out to me for near-term reversal potential
12/11/11
Reply (3)

• !Report Abuse
View all 3 replies
Alan Brochstein: The CardioMEMS panel ruling has an immaterial impact on near-term financials, though it is disappointing.
12/11/11
• !Report Abuse
Ocean Man: Minor bad news that hits harder than it should = stocks on sale.
12/11/11
• !Report Abuse
Add a reply...

140 characters

fmhaynes11
Did STJ deserve the hit caused by FDA ruling on CardioMEMS heart implant device ? Is STJ that reliant on that technology ?
12/9/11
Reply (1)

• !Report Abuse
View all 1 replies
fmhaynes11: I'm thinking of selling some STJ puts Monday if stock opens where it closed.
12/9/11
• !Report Abuse
Add a reply...

140 characters

STJ St. Jude Medical, Inc.

STJ

St. Jude Medical, Inc.